Regardless of political affiliation, the public supports congressional action to allow the federal government to negotiate prices.
Lowering prescription drug prices is a top priority for Democrats, independents, and Republicans alike, according to Kaiser Family Foundation’s latest Health Tracking Poll.
Nearly nine in 10 (88%) of those who participated in the poll favor allowing the federal government to negotiate for lower prices on medications (see Figure 1), including three-fourths (77%) of Republicans, nine in 10 independents (89%) and 96% of Democrats. Majorities of Democrats (66%), independents (56%), and Republicans (58%) also say placing a limiting on out-of-pocket costs like prescription drug costs for seniors is a top priority..
Survey respondents say profits made by pharmaceutical companies are the largest factor contributing to the price of prescription drugs. This is followed by about seven in 10 who say the cost of research and development is a major factor contributing to the price, and about half saying that the cost of marketing and advertising is a major contributing factor to the cost of prescription drugs.
About half adults say they are currently taking at least one prescription drug and about a quarter say they currently take four of more prescription medications. Twice as many of those taking four or more prescription drugs say they have difficulty affording their prescriptions (35%), compared with adults who currently take three or fewer prescription medications (17%).
Credit: KFF Health Tracking Poll
Navitus to Offer Unbranded Stelara Biosimilar, Remove Stelara from Formulary
March 13th 2025Lumicera Health Services, Navitus’ specialty pharmacy, has made a deal with Teva to offer an unbranded biosimilar that they estimate will save $112,000 and $336,000 per patient per year. Navitus will remove Stelara from formulary on July 1, 2025.
Read More
FDA Approves Neffy 1 mg Nasal Spray for Pediatric Patients
March 6th 2025Neffy 1 mg is now approved by the FDA to treat pediatric patients who weigh 33 to 65 lbs. Neffy was first FDA-approved as a 2 mg dose in August 2024 for the emergency treatment of anaphylaxis in children and adults weighing at least 66 lbs.
Read More